These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Lamb HM; Figgitt DP; Faulds D Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. Moellering RC; Linden PK; Reinhardt J; Blumberg EA; Bompart F; Talbot GH J Antimicrob Chemother; 1999 Aug; 44(2):251-61. PubMed ID: 10473233 [TBL] [Abstract][Full Text] [Related]
4. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234 [TBL] [Abstract][Full Text] [Related]
5. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. Linden PK; Pasculle AW; McDevitt D; Kramer DJ J Antimicrob Chemother; 1997 May; 39 Suppl A():145-51. PubMed ID: 9511079 [TBL] [Abstract][Full Text] [Related]
8. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases. Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811 [TBL] [Abstract][Full Text] [Related]
9. Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children. Gray JW; Darbyshire PJ; Beath SV; Kelly D; Mann JR Pediatr Infect Dis J; 2000 Mar; 19(3):234-8. PubMed ID: 10749466 [TBL] [Abstract][Full Text] [Related]
10. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685 [TBL] [Abstract][Full Text] [Related]
11. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318 [TBL] [Abstract][Full Text] [Related]
12. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance. Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781 [TBL] [Abstract][Full Text] [Related]
15. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. Klastersky J Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361 [TBL] [Abstract][Full Text] [Related]
17. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986 [TBL] [Abstract][Full Text] [Related]
18. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Dowzicky M; Talbot GH; Feger C; Prokocimer P; Etienne J; Leclercq R Diagn Microbiol Infect Dis; 2000 May; 37(1):57-62. PubMed ID: 10794942 [TBL] [Abstract][Full Text] [Related]
19. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Aeschlimann JR; Zervos MJ; Rybak MJ Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782 [TBL] [Abstract][Full Text] [Related]
20. Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Manzella JP Am Fam Physician; 2001 Dec; 64(11):1863-6. PubMed ID: 11764864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]